These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 31189583)

  • 21. Prevention of Antibiotic-Nonsusceptible Invasive Pneumococcal Disease With the 13-Valent Pneumococcal Conjugate Vaccine.
    Tomczyk S; Lynfield R; Schaffner W; Reingold A; Miller L; Petit S; Holtzman C; Zansky SM; Thomas A; Baumbach J; Harrison LH; Farley MM; Beall B; McGee L; Gierke R; Pondo T; Kim L
    Clin Infect Dis; 2016 May; 62(9):1119-25. PubMed ID: 26908787
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative incidence dynamics and serotypes of meningitis, bacteremic pneumonia and other-IPD in young children in the PCV era: Insights from Israeli surveillance studies.
    Ben-Shimol S; Givon-Lavi N; Grisaru-Soen G; Megged O; Greenberg D; Dagan R;
    Vaccine; 2018 Aug; 36(36):5477-5484. PubMed ID: 28579230
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Early impact of sequential introduction of 7-valent and 13-valent pneumococcal conjugate vaccine on IPD in Israeli children <5 years: an active prospective nationwide surveillance.
    Ben-Shimol S; Greenberg D; Givon-Lavi N; Schlesinger Y; Somekh E; Aviner S; Miron D; Dagan R
    Vaccine; 2014 Jun; 32(27):3452-9. PubMed ID: 24690148
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of pneumococcal conjugate vaccine (PCV7 and PCV13) on pneumococcal invasive diseases in Italian children and insight into evolution of pneumococcal population structure.
    Camilli R; D'Ambrosio F; Del Grosso M; Pimentel de Araujo F; Caporali MG; Del Manso M; Gherardi G; D'Ancona F; Pantosti A;
    Vaccine; 2017 Aug; 35(35 Pt B):4587-4593. PubMed ID: 28716556
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A surveillance system of Invasive Pneumococcal Disease in North-Eastern Italy.
    Baldovin T; Lazzari R; Russo F; Bertoncello C; Buja A; Furlan P; Cocchio S; Palù G; Baldo V
    Ann Ig; 2016; 28(1):15-24. PubMed ID: 26980506
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality.
    Harboe ZB; Dalby T; Weinberger DM; Benfield T; Mølbak K; Slotved HC; Suppli CH; Konradsen HB; Valentiner-Branth P
    Clin Infect Dis; 2014 Oct; 59(8):1066-73. PubMed ID: 25034421
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of the 13-valent pneumococcal conjugate vaccine (pcv13) on invasive pneumococcal disease and carriage in Alaska.
    Bruce MG; Singleton R; Bulkow L; Rudolph K; Zulz T; Gounder P; Hurlburt D; Bruden D; Hennessy T
    Vaccine; 2015 Sep; 33(38):4813-9. PubMed ID: 26247901
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Are risk factors associated with invasive pneumococcal disease according to different serotypes?
    Ciruela P; Soldevila N; Selva L; Hernández S; Garcia-Garcia JJ; Moraga F; de Sevilla MF; Codina G; Planes AM; Esteva C; Coll F; Cardeñosa N; Jordan I; Batalla J; Salleras L; Muñoz-Almagro C; Domínguez A
    Hum Vaccin Immunother; 2013 Mar; 9(3):712-9. PubMed ID: 23295982
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serotype distribution of invasive Streptococcus pneumoniae in Canada after the introduction of the 13-valent pneumococcal conjugate vaccine, 2010-2012.
    Demczuk WH; Martin I; Griffith A; Lefebvre B; McGeer A; Lovgren M; Tyrrell GJ; Desai S; Sherrard L; Adam H; Gilmour M; Zhanel GG; ;
    Can J Microbiol; 2013 Dec; 59(12):778-88. PubMed ID: 24313450
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of 10- and 13-valent pneumococcal conjugate vaccines on incidence of invasive pneumococcal disease in children aged under 16 years in Germany, 2009 to 2012.
    Weiss S; Falkenhorst G; van der Linden M; Imohl M; von Kries R
    Euro Surveill; 2015 Mar; 20(10):21057. PubMed ID: 25788255
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pneumococcal disease in South Australia: vaccine success but no time for complacency.
    Johnson DR; D'Onise K; Holland RA; Raupach JC; Koehler AP
    Vaccine; 2012 Mar; 30(12):2206-11. PubMed ID: 22273663
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Indirect effects of paediatric conjugate vaccines on invasive pneumococcal disease in older adults.
    Ciruela P; Broner S; Izquierdo C; Pallarés R; Muñoz-Almagro C; Hernández S; Grau I; Domínguez A; Jané M;
    Int J Infect Dis; 2019 Sep; 86():122-130. PubMed ID: 31283992
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of introduction of conjugate vaccines in the vaccination schedule on the incidence of pediatric invasive pneumococcal disease requiring hospitalization in Madrid 2007 to 2011.
    Picazo J; Ruiz-Contreras J; Casado-Flores J; Giangaspro E; García-de-Miguel MJ; Hernández-Sampelayo T; Otheo E; Méndez C;
    Pediatr Infect Dis J; 2013 Jun; 32(6):656-61. PubMed ID: 23249906
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Invasive Pneumococcal Disease in UK Children <1 Year of Age in the Post-13-Valent Pneumococcal Conjugate Vaccine Era: What Are the Risks Now?
    Kent A; Makwana A; Sheppard CL; Collins S; Fry NK; Heath PT; Ramsay M; Ladhani SN
    Clin Infect Dis; 2019 Jun; 69(1):84-90. PubMed ID: 30281069
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serotypes, antimicrobial susceptibility, and molecular epidemiology of invasive and non-invasive Streptococcus pneumoniae isolates in paediatric patients after the introduction of 13-valent conjugate vaccine in a nationwide surveillance study conducted in Japan in 2012-2014.
    Nakano S; Fujisawa T; Ito Y; Chang B; Suga S; Noguchi T; Yamamoto M; Matsumura Y; Nagao M; Takakura S; Ohnishi M; Ihara T; Ichiyama S
    Vaccine; 2016 Jan; 34(1):67-76. PubMed ID: 26602268
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is It Time To Review The Vaccination Strategy To Protect Adults Against Invasive Pneumococcal Disease?
    Corcoran M; Mereckiene J; Murchan S; McElligott M; ’Flanagan D; Cotter S; Cunney R; Humphreys H
    Ir Med J; 2019 Mar; 112(3):894. PubMed ID: 30968681
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of the 13-Valent Pneumococcal Conjugate Vaccine Among Adults: A Systematic Review and Meta-analysis.
    Vadlamudi NK; Chen A; Marra F
    Clin Infect Dis; 2019 Jun; 69(1):34-49. PubMed ID: 30312379
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of 13-valent pneumococcal conjugate vaccine (PCV13) in a pandemic similar to the 2009 H1N1 in the United States.
    McGarry LJ; Gilmore KE; Rubin JL; Klugman KP; Strutton DR; Weinstein MC
    BMC Infect Dis; 2013 May; 13():229. PubMed ID: 23687999
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reduced incidence of invasive pneumococcal disease after introduction of the 13-valent conjugate vaccine in Navarre, Spain, 2001-2013.
    Guevara M; Ezpeleta C; Gil-Setas A; Torroba L; Beristain X; Aguinaga A; García-Irure JJ; Navascués A; García-Cenoz M; Castilla J;
    Vaccine; 2014 May; 32(22):2553-62. PubMed ID: 24674661
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nationwide Trends of Invasive Pneumococcal Disease in Spain From 2009 Through 2019 in Children and Adults During the Pneumococcal Conjugate Vaccine Era.
    de Miguel S; Domenech M; González-Camacho F; Sempere J; Vicioso D; Sanz JC; Comas LG; Ardanuy C; Fenoll A; Yuste J
    Clin Infect Dis; 2021 Dec; 73(11):e3778-e3787. PubMed ID: 32990303
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.